Analysts feel even this may not induce many shareholders to sell.

Also Read   Related Stories News Now - GMDC Q4 net up 11% at Rs 70 cr; declares 100% dividend - JSW Steel gains 6% on fund raising plan - Sensex gains 186pts on F&O expiry - India Infoline allots ESOS; stock slips 2.5% - L&T adds 2% on good Q4 numbers - Britannia falls 3% on dip in FY09 net   Also Read   Related Stories News Now - Markets end with marginal losses - FII-TO-FII TRADES: PNB traded at 7% premium - Haldia Petrochem strike called off - Investors should be made aware of risks: Bhave - NSE's new MF service system from Nov 30 More

Switzerland-based Novartis AG, the parent company of Novartis India, has formally revised the open-offer price for its shares to Rs 450 from Rs 351 to buy back an additional stake of up to 39 per cent, to take its shareholding in the Indian subsidiary to 90 per cent.

Following the announcement, the share price of Novartis India surged 20 per cent to hit the upper circuit at Rs 467.50 in morning trade on the Bombay Stock Exchange (BSE). It closed at Rs 444.80, 14.17 per cent higher than yesterday’s closing price of Rs 389.60.

However, analysts say even with the revised price, Novartis India is unlikely to get a good response from shareholders. “Novartis India’s share prices are (already) ruling at a price close to Rs 450 and, in this scenario, investors are unlikely to surrender their shares as the transaction attracts capital gains tax,” said Ranjit Kapadia, vice-president for institution-research at HDFC Securities.

With the revised price, the Basel-based multinational drug major will have to pay around Rs 560 crore to successfully purchase the extra 39 per cent shares; it was earlier planning to spend about Rs 440 crore. The offer, announced last month, was at a premium of 35 per cent over Novartis India’s average share price during March.

The revised offer represents a premium of 63 per cent to the closing share price of Rs 275.6 on March 24, the last trading day before announcement of the offer, said a statement from Novartis AG.

“This proposal represents Novartis’ only and final price revision to this offer, as May 28 is the last day on which the price can be revised,” said the statement.

DSP Merrill Lynch represents Novartis AG for the offer, which started on May 20 and is scheduled to close on June 8, 2009. Currently Novartis AG holds 50.93 per cent stake in the Rs 560 crore Indian subsidiary. The company has been engaged in prolonged legal battles with the Indian government and the patent office on the patent validity of its cancer drug, Glivec.

Other Stories      - Markets end with marginal losses - FII-TO-FII TRADES: PNB traded at 7% premium - Haldia Petrochem strike called off - Investors should be made aware of risks: Bhave - NSE's new MF service system from Nov 30 More

Tags : Novartis AG | BSE | Merrill Lynch   Read Business news in  Advertisements   Get financial advisory and solutions for your projects   Holidays starting at a delightful EMI of Rs 3481   Switch on and say hello to Monday morning !   Your dream home can now be a reality.   Visit Fortis for a preventive health check-up & get a 20% discount.   Follow the ups and downs of your investments. Try our new Portfolio Tracker   Kolkata Dock \ Freight contract for the British Gurkhas Nepal   Find how Midsize Businesses use ERP to gain competitive advantage   Trading in Forex is now as easy as 1-2-3   Discover an economical and cost effective way to market your products and services   Giftwithlove.com: Same day delivery of Flowers and Cakes to India   Download the E-book on the Future of Business Intelligence   Learn Best Practices for improving customer satisfaction   Know your customers better... download the free e-book on CRM